Anthropic Nears $15 Billion Credit Deal Ahead of IPO 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Nears Astra AI Model Launch With Safety Focus 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
Lenovo Shares Fall After Dropbox Security Breach Exposes ID Vulnerability 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Audi, SAIC Launch China Innovation Hub for New AUDI Models 
Deutsche Telekom Shares Rise as Elliott Pushes Against T-Mobile Merger 
Add as a preferred source on Google
PARSIPPANY, N.J., March 06, 2018 -- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that the company is scheduled to participate in an analyst-led fireside chat at the 2018 Barclays Global Healthcare Conference at 11:15 AM ET on Tuesday, March 13, 2018 in Miami.
A live audio webcast of the Pacira presentation can be accessed by visiting the “Investors & Media” section of the company’s website at investor.pacira.com. A replay of the webcast will be archived on the Pacira website for two weeks following the presentation date.
About Pacira
Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) is a specialty pharmaceutical company dedicated to advancing and improving postsurgical outcomes for acute care practitioners and their patients. The company’s flagship product, EXPAREL® (bupivacaine liposome injectable suspension) was commercially launched in the United States in April 2012. EXPAREL utilizes DepoFoam®, a unique and proprietary product delivery technology that encapsulates drugs without altering their molecular structure, and releases them over a desired period of time. To learn more about Pacira, including the corporate mission to reduce overreliance on opioids, visit www.pacira.com.
Company Contact:
Pacira Pharmaceuticals, Inc.
Christian Pedetti
(973) 254-4387
[email protected]
